Study of Vasorin Levels to Diagnose and Predict Outcomes in Adults With Septic or Non-Septic Shock

What this Trial Is About

Researchers are evaluating Vasorin Vasn as a new biomarker for diagnosing and predicting outcomes in patients with septic shock, the most severe form of infection-related shock. This study compares plasma Vasn levels between two groups patients with septic shock and patients experiencing non-septic shock such as post-cardiac surgery vasoplegia or other types of shock without infection. The goal is to see if Vasn provides better diagnostic accuracy than current markers like procalcitonin and to assess its link with patient survival over 28 days. Participants are divided into two groups based on their shock type septic shock with infection and non-septic shock without infection. Blood samples will be taken to measure Vasn concentrations at day 0, day 1, and day 3. Researchers will also correlate Vasn levels with clinical factors including noradrenaline dose, kidney injury occurrence, coagulation markers, organ failure scores SOFA, and length of hospital stay. During the study, patients admitted to intensive care for less than 24 hours will have blood drawn to assess Vasn levels and other laboratory markers. The study will track how Vasn levels relate to illness severity, treatment needs, and survival over the first three days and up to 28 days after admission. This information aims to help improve diagnosis and treatment decisions for patients with different types of shock.

Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock